IQWiG report on Eliquis (BMS/Pfizer) for Stroke Prevention associated with Atrial Fibrillation

The Institute for Quality and Efficiency in Healthcare (IQWiG)in Germany said that Eliquis (apixaban) from BMS and partner Pfizer Inc.has "significant" additional benefit to prevent Stroke and Systemic Embolism in adults with non-valvular atrial fibrillation (AF) with one or more risk factors -- an indication approved by the European Commission in November.

IQWiG said Eliquis provides "significant" additional benefit over vitamin K antagonists in people 65 years of age or older who are still eligible for treatment with a vitamin K antagonist, and over aspirin in all people ineligible for treatment with a vitamin K antagonist -- the comparators requested by Germany's Federal Joint Committee (G-BA). The institute said Eliquis has no additional benefit for patients younger than 65 years of age who are still eligible for treatment with a vitamin K antagonist. The partners have until April 23 to respond. A final benefit assessment from G-BA is expected in mid-June 2013.